Abstract
There has long been a concern that all psychotropics may have adverse cardiac effects including prolongation of the QT interval. The recent expanded use of the atypical antipsychotics has increased these concerns. This is a selective review of the effect of the major classes of psychotropic drugs on the QT interval. The review also includes a review of methadone given the high co-morbidity between major psychiatric disorders and substance use disorders.
Keywords: Acquired LQTS, drug-induced QT syndrome, methadone, psychiatry, psychotropics, QT interval, QT prolongation, sudden cardiac death, cardiometabolic risk, arrhythmogenic, mesoridazine, phenothiazines, hypomagnesemia, epidemiologic, tachyarrhythmias
Current Psychopharmacology
Title: Psychotropics and Methadone in Acquired Long QT Syndrome
Volume: 1
Author(s): Stephan Carlson and Russell Joffe
Affiliation:
Keywords: Acquired LQTS, drug-induced QT syndrome, methadone, psychiatry, psychotropics, QT interval, QT prolongation, sudden cardiac death, cardiometabolic risk, arrhythmogenic, mesoridazine, phenothiazines, hypomagnesemia, epidemiologic, tachyarrhythmias
Abstract: There has long been a concern that all psychotropics may have adverse cardiac effects including prolongation of the QT interval. The recent expanded use of the atypical antipsychotics has increased these concerns. This is a selective review of the effect of the major classes of psychotropic drugs on the QT interval. The review also includes a review of methadone given the high co-morbidity between major psychiatric disorders and substance use disorders.
Export Options
About this article
Cite this article as:
Carlson Stephan and Joffe Russell, Psychotropics and Methadone in Acquired Long QT Syndrome, Current Psychopharmacology 2012; 1 (2) . https://dx.doi.org/10.2174/2211556011201020183
DOI https://dx.doi.org/10.2174/2211556011201020183 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Inhibitors of the Aspartyl Protease Renin for the Treatment of Hypertension
Current Protein & Peptide Science Biomarkers of Lung Tissue Remodeling in Pulmonary Diseases: Implications for Clinical Practice and Research
Current Respiratory Medicine Reviews A Combination of 3D-QSAR Modeling and Molecular Docking Approach for the Discovery of Potential HIF Prolyl Hydroxylase Inhibitors
Medicinal Chemistry Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry Ezetimibe and Vascular Inflammation
Current Vascular Pharmacology The Future of Diabetes Management by Healthy Probiotic Microorganisms
Current Diabetes Reviews Calcium Ions in Inherited Cardiomyopathies
Medicinal Chemistry Pleiotropic Effects of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors: Candidate Mechanisms for Anti-Lipid Deposition in Blood Vessels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Law-Medicine Interfacing: Patenting of Human Genes and Mutations
Recent Patents on DNA & Gene Sequences Current Advances in the Treatment of Parkinsons Disease with Stem Cells
Current Neurovascular Research Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease
Current Pharmaceutical Design Resveratrol and Ischemic Preconditioning in the Brain
Current Medicinal Chemistry Getting Patients to Target- Implementing the Guidelines
Current Vascular Pharmacology Genetic Variation in the β2-Adrenergic Receptor: Impact on Intermediate Cardiovascular Phenotypes
Current Pharmacogenomics and Personalized Medicine Herb-Drug Interactions: An Insight into Cardiovascular Diseases Based on Case Reports
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issue: Disease Control and Active and Healthy Ageing: New Paradigms of Therapeutic Strategy)
Current Pharmaceutical Design Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Season of Birth Effects on Reproduction in Women
Current Women`s Health Reviews Integrin (αvβ3) Targeted RGD Peptide Based Probe for Cancer Optical Imaging
Current Protein & Peptide Science Inhibitory Effect of Copper on Cystathionine β-Synthase Activity: Protective Effect of an Analog of the Human Albumin N-Terminus
Protein & Peptide Letters